Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines

Cancer Research

Volumn 58, Issue 7, 1998, Pages 1486-1493

  Pulaski, Beth A ^a   Ostrand Rosenberg, Suzanne ^a  

^a UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; BREAST METASTASIS; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; ANTIGENS, CD80; ANTIMETABOLITES, ANTINEOPLASTIC; CANCER VACCINES; CELL DIVISION; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNOTHERAPY, ACTIVE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; T-LYMPHOCYTES; THIOGUANINE; TRANSFECTION;

EID: 0032053794     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Vogel, C. L. Hormonal approaches to breast cancer treatment and prevention: an overview. Semin. Oncol., 23 (Suppl.): 2s-9s, 1996.
2. Seidman, A. D. Chemotherapy for advanced breast cancer. Semin. Oncol., 23 (Suppl.): 55s-59s, 1996.
3. Vandat, L., Raptis, G., Fennelly, D., and Crown, J. High-dose chemotherapy of metastatic breast cancer: a review. Cancer Invest., 13: 505-510, 1995.
4. Fisher, B., Anderson, S., Redmond, C. K., Wolmark, N., Wickerham, D. C., and Cronin, W. M. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with and without irradiation in the treatment of breast cancer. N. Engl. J. Med., 333: 1456-1461, 1995.
5. Harris, J., Morrow, M., and Norton, L. Cancer of the breast. In: V. T. Devita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer, Principles and Practice of Oncology, Ed. 5, Vol. 2, pp. 1602-1616. Philadelphia: Lippincott-Raven, 1997.
6. Blankenstein, T., Cayeux, S., and Qin, Z. Genetic approaches to cancer immunotherapy. Rev. Physiol. Biochem. Phannacol., 129: 1-49, 1996.
7. Hellstrom, K. E., Hellstrom, I., and Chen, L. Can co-stimulated tumor immunity be therapeutically efficacious? Immunol. Rev., 145: 123-145, 1995.
8. Ostrand-Rosenberg, S., Baskar, S., Patterson, N., and Clements, V. Expression of MHC class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells. Tissue Antigens. 47: 414-421, 1996.
9. + tumor cells are potent vaccines for stimulating tumor rejection in tumorbearing mice. J. Exp. Med., 181: 619-628, 1995.
10. Asher, A. L., Mule, J. J., Kasid, A., Restifo, N. P., Salo, J. C., Reichert, C. M., Jaffe, G., Fendly, B., Kreigler, M., and Rosenberg, S. A. Murine tumor cells transduced with the gene for tumor necrosis factor-α: evidence for paracrine immune effects of tumor necrosis factor against tumors. J. Immunol., 146: 3227-3234, 1991.
11. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D., and Mulligan, R. C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA, 90: 3539-3543, 1993.
12. Pulaski, B. A., McAdam, A. J., Hutter, E. K., Biggar, S., Lord, E. M., and Frelinger, J. G. Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dependent mechanism. Cancer Res., 53: 2112-2117, 1993.
13. Li, Y., Hellstrom, E. K., Newby, S. A., and Chen, L. Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors. J. Exp. Med., 183: 639-644, 1996.
14. Rodolfo, M, Zilocchi, C., Melani, C., Cappetti, B., Arioli, I., Parmiani, G., and Colombo, M. P. Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens. Comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines. J. Immunol., 157: 5536-5542, 1996.
15. Chamberlain, R. S., Carroll, M. W., Bronte, V., Hwu, P., Warren, S., Yang, J. C., Nishimura, M., Moss, B., Rosenberg, S. A., and Restifo, N. P. Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. Cancer Res., 56: 2832-2836, 1996.
16. Zitvogel, L., Tahara, H., Robbins, P. D., Storkus, W. J., Clarke, M. R., Nalesnik, M. A., and Lotze, M. T. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J. Immunol., 155: 1393-1403, 1995.
17. Zheng, L. M., Ojcius, D. M., Garaud, F., Roth, C., Maxwell, E., Li, Z., Rong, H., Chen, J., Wang, X. Y., Catino, J. J., and King, I. Interleukin-10 inhibits tumor metastases through an NK cell-dependent mechanism. J. Exp. Med., 184: 579-584, 1996.
18. Coveney, E., Clary, B., Iacobucci, M., Philip, R., and Lyerly, K. Active immunotherapy with transiently transfected cytokine-secreting tumor cells inhibits breast cancer metastases in tumor-bearing animals. Surgery (St. Louis), 120: 265-272, 1996.
19. Porgador, A., Tzehoval, E., Vadai, E., Feldman, M., and Eisenbach, L. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases. Cancer Res., 55: 4941-4149, 1995.
20. Janeway, C. A., Jr., and Bottomly, K. Responses of T cells to ligands for the T-cell receptor. Semin. Immunol., 8: 108-115, 1996.
21. Sperling, A. I., and Bluestone, J. A. The complexities of T-cell co-stimulation: CD28 and beyond. Immunol. Rev., 153: 155-182, 1996.
22. Chambers, C. A., and Allison, J. P. Co-stimulation in T cell responses. Curr. Opin. Immunol., 9: 396-404, 1997.
23. + lymphocytes. J. Immunol., 148: 1985-1992, 1992.
24. Liu, Y., Jones, B., Aruffo, A., Sullivan, K. M., Linsley, P. S., and Janeway, C. A., Jr. Heat-stable antigen is a co-stimulatory molecule for CD4 T cell growth. J. Exp. Med., 175: 437-445, 1992.
25. Liu, Y., Jones, B., Brady, W., Janeway, C. A., Jr, and Linsley, P. S. Co-stimulation of murine CD4 T cell growth: cooperation between B7 and heat-stable antigen. Eur. J. Immunol., 22: 2855-2859, 1992.
26. DeBenedette, M. A., Chu, N. R., Pollok, K. E., Hurtado, J., Wade, W. F., Kwon, B. S., and Watts, T. H. Role of 4-1BB- ligand in costimulation of T lymphocyte growth and its upregulation on M12 B lymphomas by cAMP. J. Exp. Med., 181: 985-992, 1995.
27. Hurtado, J., Kim, S. H., Pollock, K. E., Lee, Z. H., and Kwon, B. S. Potential role of 4-1BB in T-cell activation: comparison with the costimulatory molecule CD28. J. Immunol., 155: 3360-3367, 1995.
28. Dexter, D. L., Kowalski, H. M., Blazar, B. A., Fligiel, Z., Vogel, R., and Heppner, G. H. Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res., 38: 3174-3181, 1978.
29. Miller, F. R., Miller, B. E., and Heppner, G. H. Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invasion Metastasis, 3: 22-31, 1983.
30. Aslakson, C. J., and Miller, F. R. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res., 52: 1399-1405, 1992.
31. Gunning, P., Leavitt, J., Muscat, G., Ng, S-Y., and Kedes, L. A human β-actin expression vector system directs high-level accumulation of antisense transcripts. Proc. Natl. Acad. Sci. USA, 84: 4831-4835, 1987.
32. Yeh, K-Y., Pulaski, B. A., Woods, M. L., McAdam, A. J., Gaspari, A. A., Frelinger, J. G., and Lord, E. M. B7-1 enhances natural killer cell-mediated cytotoxicity and inhibits tumor growth of a murine lung adenocarcinoma. Cell. Immunol., 165: 217-224, 1995.
33. d antigens on the surface of these cells. Transplantation (Baltimore), 34: 113-118, 1982.
34. Ozato, K., Mayer, N. M., and Sachs, D. H. Hybridoma cell lines secreting monoclonal antibodies to mouse H-2 and Ia antigens. J. Immunol., 124: 533-540, 1980.
35. Kappler, J. W., Skidmore, B., White, J., and Marrack, P. Antigen-inducible, H-2-restricted, IL-2-producing T cell hybridomas. Lack of independent antigen and H-2 recognition. J. Exp. Med., 153: 1198-1214, 1981.
36. Janeway, C. A., Jr, Conrad, P. J., Lerner, E. A., Babich, J., Wettstein, P., and Murphy, D. B. Monoclonal antibodies specific for Ia glycoproteins raised by immunization with activated T cells: possible role of T cell-bound Ia antigens as targets of immunoregulatory T cells. J. Immunol., 132: 662-667, 1984.
37. Nabavi, N., Freeman, G. J., Gault, A., Godfrey, D., Nadler, L. M., and Glimcher, L. M. Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression. Nature (Lond.), 360: 266-268, 1992.
38. Rutgers, E. J. Th., van Slooten, E. A., and Kluck, H. M. Follow-up treatment of primary breast cancer. Br. J. Surg., 76: 187-190, 1989.
39. Tomin, R., and Donegan, W. L. Screening for recurrent breast cancer-its effectiveness and prognostic value. J. Clin. Oncol., 5: 62-67, 1987.
40. Kamby, C., Dirksen, H., Vejborg, I., Daugaard, S., Guldhammer, B., Rossing, N., and Mouridsen, H. T. Incidence and methodologic aspects of the occurrence of liver metastases in recurrent breast cancer. Cancer, 59: 1524-1529, 1987.
41. Amer, M. H. Chemotherapy and pattern of metastases in breast cancer patients. J. Surg. Oncol., 19: 101-105, 1982.
42. Boogerd, W. Central nervous system metastasis in breast cancer. Radiother. Oncol., 40: 5-22, 1996.
43. Geldhof, A. B., Raes, G., Bakkus, M., Devos, S., Thielemans, K., and DeBaetselier, P. Expression of B7-1 by highly metastatic mouse T lymphomas induces optimal natural killer cell-mediated cytotoxicity. Cancer Res., 55: 2730-2733, 1995.
44. Hart, I. R., and Fidler, I. J. The implications of tumor heterogeneity for studies on the biology and therapy of cancer metastases. Biochim. Biophys. Acta, 651: 37-50, 1981.
45. Ostrand-Rosenberg, S., Thakur, A., and Clements, V. Rejection of mouse sarcoma cells after transfection of MHC class II genes. J. Immunol., 144: 4068-4071, 1990.
46. + T lymphocytes. J. Immunol., 160: 661-666, 1998.
47. Armstrong, T. D., Pulaski, B. A., and Ostrand-Rosenberg, S. Tumor antigen presentation: changing the rules. Cancer Immunol. Iminunother., in press, 1998.
48. Huang, A., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., and Levitsky, H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (Washington DC), 264: 961-965, 1995.
49. Huang, A., Bruce, A., Pardoll, D., and Levitsky, H. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J. Exp. Med., 183: 769-776, 1996.
50. Pulaski, B. A., Yeh, K-Y., Shastri, N., Maltby, K. M., Penney, D., Lord, E., and Frelinger, J. G. IL-3 enhances CTL development and class I MHC presentation of exogenous antigen by tumor-infiltrating macrophages. Proc. Natl. Acad. Sci. USA, 93: 3669-3674, 1996.
51. Levey, D. L., and Srivastava, P. K. Alterations in T cells of cancer-bearers: whence specificity? Immunol. Today, 17: 365-368, 1996.
52. Rosenberg, S. A. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today, 18: 175-182, 1997.
53. Van den Eynde, B. J., and van der Bruggen, P. T cell-defined tumor antigens. Curr. Opin. Immunol., 9: 684-693, 1997.
54. Liu, Y., and Janeway, C. Cells that present both specific ligand and costimulatory activity are the most efficient inducers of clonal expansion of normal CD4 T cells. Proc. Natl. Acad. Sci. USA, 89: 3845-3849, 1992.